BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis 2017;64:1154-62. [PMID: 28199495 DOI: 10.1093/cid/cix126] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
2 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
3 Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy 2018;62:94-103. [DOI: 10.1016/j.drugpo.2018.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
4 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412-424. [PMID: 29773899 DOI: 10.1038/s41575-018-0026-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
5 Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L; EuroSIDA study group. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Med 2021. [PMID: 34882940 DOI: 10.1111/hiv.13212] [Reference Citation Analysis]
6 Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M, Alvarez M, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol 2018;69:1007-14. [PMID: 30142429 DOI: 10.1016/j.jhep.2018.07.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 14.8] [Reference Citation Analysis]
7 Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators . Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. Open Forum Infect Dis 2019;6:ofz055. [PMID: 30882016 DOI: 10.1093/ofid/ofz055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
9 Gutiérrez García ML, Gómez Perosanz R, Acedo Sanz JM, Delgado-Iribarren García-Campero A, Claudio Domínguez I, Domenech Gómez-Imaz A, Pérez Encinas M, de la Fuente Hermosín I, Fabero Jimenez A, Fernández Rodríguez CM. Coordinated assistance plan for the elimination of hepatitis C virus at the centro de ayuda integral al drogodependiente (CAID (Comprehensive Care Centre for Drug Addicts)). Gastroenterol Hepatol 2021;44:214-20. [PMID: 33162188 DOI: 10.1016/j.gastrohep.2020.08.002] [Reference Citation Analysis]
10 Huang MH, Chang SY, Liu CH, Cheng A, Su LH, Liu WC, Su YC, Sun HY, Hung CC, Chang SC. HCV reinfections after viral clearance among HIV-positive patients with recent HCV infection in Taiwan. Liver Int 2019;39:1860-7. [PMID: 31343813 DOI: 10.1111/liv.14199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
11 Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases 2020;71:1502-10. [DOI: 10.1093/cid/ciz985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
12 Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ;  SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153-161. [PMID: 29310928 DOI: 10.1016/s2468-1253(17)30404-1] [Cited by in Crossref: 135] [Cited by in F6Publishing: 63] [Article Influence: 33.8] [Reference Citation Analysis]
13 Busschots D, Kremer C, Koc ÖM, Heyens L, Bielen R, Apers L, Florence E, Messiaen P, Van Laethem K, Van Wijngaerden E, Nevens F, Hens N, Robaeys G. The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination. Int J Infect Dis 2021;105:217-23. [PMID: 33610786 DOI: 10.1016/j.ijid.2021.02.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Clement ME, Collins LF, Wilder JM, Mugavero M, Barker T, Naggie S. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. Infect Dis Clin North Am 2018;32:407-23. [PMID: 29778263 DOI: 10.1016/j.idc.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
15 Breskin A, Westreich D, Hurt CB, Cole SR, Hudgens MG, Seaberg EC, Thio CL, Tien PC, Adimora AA. The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus. Clin Infect Dis 2019;69:1613-20. [PMID: 30615096 DOI: 10.1093/cid/ciz008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25:220-227. [PMID: 29316030 DOI: 10.1111/jvh.12859] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
17 Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology 2020;72:643-57. [DOI: 10.1016/j.jhep.2019.11.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
18 Newsum AM, Matser A, Schinkel J, van der Valk M, Brinkman K, van Eeden A, Lauw FN, Rijnders BJA, van de Laar TJW, van de Kerkhof M, Smit C, Boyd A, Arends JE, Prins M; MSM Observational Study of Acute Infection with hepatitis C (MOSAIC) study group. Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis. Clin Infect Dis 2021;73:460-7. [PMID: 32459339 DOI: 10.1093/cid/ciaa645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Martínez-Rebollar M, De La Mora L, Campistol M, Cabrera B, Bagué A, De Lazzari E, Torres B, González-Cordón A, Inciarte A, Ambrosioni J, Martínez E, Blanco JL, Forns X, Blanch J, Mallolas J, Laguno M. Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. Infect Dis Ther 2021;10:1253-66. [PMID: 33914265 DOI: 10.1007/s40121-021-00448-0] [Reference Citation Analysis]
20 Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG; VHICS Study Team. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018;5:ofy103. [PMID: 29977962 DOI: 10.1093/ofid/ofy103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
21 Oikonomou KG, Tsai E, Sarpel D, Dieterich DT. Liver Disease in Human Immunodeficiency Virus Infection. Clin Liver Dis 2019;23:309-29. [PMID: 30947879 DOI: 10.1016/j.cld.2018.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Selfridge M, Cunningham EB, Barnett T, Drost A, Gray-Schleihauf C, Guarasci K, Lundgren K, Milne R, Grebely J, Fraser C. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy 2021;96:103418. [PMID: 34538704 DOI: 10.1016/j.drugpo.2021.103418] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Su PS, Su CW, Wu SH, Wei TH, Chu CJ, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. J Chin Med Assoc 2021;84:465-71. [PMID: 33871393 DOI: 10.1097/JCMA.0000000000000528] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME. Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment? Expert Rev Anti Infect Ther 2018;16:411-22. [PMID: 29722275 DOI: 10.1080/14787210.2018.1471355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. AIDS 2020;34:1347-58. [PMID: 32590433 DOI: 10.1097/QAD.0000000000002562] [Reference Citation Analysis]
26 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
27 Hoornenborg E, Coyer L, Boyd A, Achterbergh RCA, Schim van der Loeff MF, Bruisten S, de Vries HJC, Koopsen J, van de Laar TJW, Prins M; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. J Hepatol 2020;72:855-64. [PMID: 31862485 DOI: 10.1016/j.jhep.2019.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
28 Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferrière V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. AIDS 2019;33:1013-22. [PMID: 30946155 DOI: 10.1097/QAD.0000000000002156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Martinello M, Dore GJ, Matthews GV, Grebely J. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infect Dis Clin North Am 2018;32:371-93. [PMID: 29778261 DOI: 10.1016/j.idc.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
30 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
31 Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22 Suppl 6:e25348. [PMID: 31468692 DOI: 10.1002/jia2.25348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
32 Cachay ER, Hill L, Torriani F, Ballard C, Grelotti D, Aquino A, Christopher Mathews W. Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV. Open Forum Infect Dis 2018;5:ofy173. [PMID: 30090840 DOI: 10.1093/ofid/ofy173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
33 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
34 Hsu J, Hsu P, Shie C, Chuah S, Wu I, Huang W, Tang S, Tsai K, Kuo L, Ghose S, Hsu J, Shih C. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina 2022;58:436. [DOI: 10.3390/medicina58030436] [Reference Citation Analysis]